Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03868124 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
A Phase 3 study, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT03868124: Completed Phase 3 study, sponsored by Glaukos Corporation.
NCT03868124 is a Phase 3 study that has completed, run by Glaukos Corporation. The registered enrollment target is 560 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03868124, a Phase 3 study, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT)
Primary Outcome
Change from time-matched baseline in IOP at 8AM and 10AM at Day 10, Week 6 and Month 3. Day 10 8AM IOP minus Baseline 8AM IOP; Day 10 10AM IOP minus Baseline 10AM IOP; Week 6 8AM IOP minus Baseline 8AM IOP; Week 6 10AM IOP minus Baseline 10AM IOP; Month 3 8AM IOP minus Baseline 8AM IOP; Month 3 10AM IOP minus Baseline 10AM IOP.
Interventions
- COMBINATION_PRODUCT G2-TR intraocular implant containing travoprost
- DRUG Sham surgery + active-comparator eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 3 |
What the finished NCT03868124 record still lists
NCT03868124 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which G2-TR intraocular implant containing travoprost is the first listed.
NCT03868124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03868124 about?
NCT03868124 is a clinical study titled "Clinical Study Comparing Two Models of a Travoprost Intraocular Implant". Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT)
What is the current status of trial NCT03868124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2018-09-17. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT03868124?
The interventions under investigation include: G2-TR intraocular implant containing travoprost (COMBINATION_PRODUCT), Sham surgery + active-comparator eye drops (DRUG).
Who is sponsoring clinical trial NCT03868124?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03868124's enrollment target sits among peer trials
560 671st of 2000 higher than 1,328 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI